Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
SLC28A1	9154	URIDINE	CHEMBL100259		NCI	10455109
SLC28A1	9154	THYMIDINE	CHEMBL52609		NCI	10353719

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
SLC28A1	rs2242047	CC	gemcitabine	efficacy	no	Response rate, median time to progression, and median survival time were not significantly different among patients with differing genotypes.	Genotype CC is not associated with increased response to gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.	18538445	981785654
SLC28A1	rs2290272	GG	gemcitabine	efficacy	no	Response rate, median time to progression, and median survival time were not significantly different among patients with differing genotypes.	Genotype GG is not associated with increased response to gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.	18538445	981785608
SLC28A1	rs8187758	CC	gemcitabine	efficacy	no	Response rate, median time to progression, and median survival time were not significantly different among patients with differing genotypes.	Genotype CC is not associated with increased response to gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.	18538445	981785622
SLC28A1	rs2242046	GG	gemcitabine	efficacy	no	Response rate, median time to progression, and median survival time were not significantly different among patients with differing genotypes.	Genotype GG is not associated with increased response to gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.	18538445	981785668
SLC28A1	rs2242048	GG	gemcitabine	"efficacy","toxicity"	no	Tumor response to therapy, progression free survival, and risk of neutropenia development did not significantly differ between genotype groups.	Genotype GG is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AA + AG.	20665488	981794096
SLC28A1	rs2242047	CC	gemcitabine	efficacy	no	as assessed by tumor progression - progessive or nonprogressive. Stats corrected with the false-discovery rate for candidate SNPs and Bonferroni method (p<0.05 was considered significant). Additive and Recessive model were not significant - dominant was (p=0.033).	Genotype CC is associated with increased response to gemcitabine in people with Colorectal Neoplasms as compared to genotype TT.	22838950	981237893
SLC28A1	rs2242048	GG	gemcitabine	efficacy	no	Response rate, median time to progression, and median survival time were not significantly different among patients with differing genotypes.	Genotype GG is not associated with increased response to gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.	18538445	981785635
SLC28A1	rs2290272	A	capecitabine	metabolism/PK	no	Please note that these alleles were listed as G and T within the paper. No significant differences in the area under the concentration-time curve from 0 to infinity (AUCinf) were seen between any of the genotypes (CC, AC, AA). Nor were any significant differences seen between these genotypes when considering the capecitabine metabolites 5'-DFCR, 5'-DFUR or 5'FU (5'-fluorouracil).	Allele A is not associated with metabolism of capecitabine in people with Breast Neoplasms as compared to allele G.	23588952	1183682310
SLC28A1	rs11853372	TT	gemcitabine	metabolism/PK	no	Gemcitabine, dFdCTP, and dFdU plasma concentrations were measured before (5, 15, 30, 45 min) and after gemcitabine infusion (1, 1.25, 1.5, 2, 6, 24, 48, 72 hrs). Population pharmacokinetic analysis of gemcitabine and metabolites (dFdU, dFdCTP) were performed by non-linear mixed effects modeling. rs11853372 is not associated with metabolism of gemcitabine.	Genotype TT is not associated with metabolism of gemcitabine as compared to genotypes GG + GT.	24300978	1184174892
SLC28A1	rs2242046	A	gemcitabine	metabolism/PK	no		Allele A is not associated with clearance of gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.	21590444	1446900828
SLC28A1	rs11853372	TT	ara-CTP	metabolism/PK	yes		Genotype TT is associated with decreased concentrations of ara-CTP in children with Leukemia, Myeloid, Acute as compared to genotypes GG + GT.	30088438	1449752006
SLC28A1	rs8187758	CC	gemcitabine	"efficacy","toxicity"	no	Tumor response to therapy, progression free survival, and risk of neutropenia development did not significantly differ between genotype groups.	Genotype CC is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AA + AC.	20665488	981794102
SLC28A1	rs17215836	TGT/TGT	gemcitabine	efficacy	no	Response rate, median time to progression, and median survival time were not significantly different among patients with differing genotypes.	Genotype TGT/TGT is not associated with increased response to gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes TGT/del + del/del.	18538445	981785594